Relmada Therapeutics (RLMD) Enterprise Value (QoQ) (2012 - 2026)

Relmada Therapeutics (RLMD) Enterprise Value (QoQ) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Relmada Therapeutics 205.29 Mn 205.29 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -151.56%
Dec 31, 2025 -569.76%
Sep 30, 2025 32.65%
Jun 30, 2025 23.80%
Mar 31, 2025 39.74%
Dec 31, 2024 17.02%
Sep 30, 2024 23.17%
Jun 30, 2024 15.76%
Mar 31, 2024 13.20%
Dec 31, 2023 9.36%
Sep 30, 2023 10.35%
Jun 30, 2023 10.50%
Mar 31, 2023 10.71%
Dec 31, 2022 19.46%
Sep 30, 2022 13.12%
Jun 30, 2022 3.94%
Mar 31, 2022 -4.12%
Dec 31, 2021 -140.57%
Sep 30, 2021 19.24%
Jun 30, 2021 -6.20%